Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Mental health

Treatment of schizophrenia should not be limited to drugs, says WHO

Treatment of schizophrenia should not be limited to pharmacotherapy but should also include psychosocial interventions, says the World Health Organization (WHO).

Mohammad Taghi Yasamy, senior medical officer at WHO’s department of mental health and substance abuse, said such interventions can also help prevent some of the side effects of antipsychotic medications.

Many antipsychotic medicines increase appetite and, if not monitored regularly, can lead patients to develop diabetes. “Diabetes among these patients was two to three times more common than the general public,” Yasamy said, adding that they also developed hyperlipidaemia, where the blood fat increased and patients developed cardiovascular diseases.

Overall, the life expectancy of people with schizophrenia is 10-25 years shorter than the general population. According to Yasamy, there are many reasons for this, including poor lifestyle, being overweight, smoking — which was 2-3 times more common among people with schizophrenia — and lack of physical activity.

However, with regular monitoring of physical health, and by tackling the side effects of medicines, people with schizophrenia could have a more normal life, says WHO.

Yasamy said the global agency believes there also needs to be a shift “from institutions to community services”.

An estimated 21 million people worldwide are suffering from schizophrenia, comprising 12 million males and 9 million females, but only about 50% are receiving services. In low- and middle-income countries, “the services gap is higher”, Yasamy said. He emphasised that the situation is generally worse in Africa in terms of services, where about 80% of people with mental illness do not receive any services for mental disorders.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066840

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.